Factors associated with the uric acid-lowering effects of sodium-glucose cotransporter-2 inhibition in patients with type 2 diabetes: Insights from the randomized PROTECT trial.

Saito, Yuichi; Tanaka, Atsushi; Imai, Takumi; Miura, Shin-Ichiro; Ajioka, Masayoshi; Kodama, Kazuhisa; Kobayashi, Yoshio; Node, Koichi

Saito, Yuichi; Tanaka, Atsushi; Imai, Takumi; Miura, Shin-Ichiro; Ajioka, Masayoshi; Kodama, Kazuhisa; Kobayashi, Yoshio; Node, Koichi.

Afiliação

Saito Y; Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Tanaka A; Department of Cardiovascular Medicine, Saga University, Saga, Japan.
Imai T; Clinical and Translational Research Center, Kobe University Hospital, Kobe, Japan.
Miura SI; Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
Ajioka M; Department of Cardiovascular Internal Medicine, Tosei General Hospital, Seto, Japan.
Kodama K; Division of Cardiology, Saiseikai Kumamoto Hospital, Kumamoto, Japan.
Kobayashi Y; Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Node K; Department of Cardiovascular Medicine, Saga University, Saga, Japan.

Diabetes Obes Metab ; 26(3): 1110-1113, 2024 Mar.

Article em En | MEDLINE | ID: mdl-37961042

Assuntos

Diabetes Mellitus Tipo 2; Humanos; Diabetes Mellitus Tipo 2/tratamento farmacológico; Ácido Úrico; Hipoglicemiantes/uso terapêutico; Hipoglicemiantes/farmacologia; Glucose; Sódio

Palavras-chave

ipragliflozin; sodium-glucose cotransporter-2 inhibitor; type 2 diabetes; uric acid

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google